dyp688
dyp688: 1 clinical trial tracked.
dyp688 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about dyp688, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
Primary endpoint: Phase I (Dose Escalation): Incidence and severity of dose limiting toxicities (DLTs) during the first 28 days of treatment.
Interventionalopen66 enrolledStarted 2022-07Completion 2027-1011 sites · Australia, France, Germany, Netherlands…Novartis Pharmaceuticals